HOME >> MEDICINE >> NEWS
SCAI president testifies before FDA on safety of drug-eluting stents

(December 7, 2006 WASHINGTON, DC) -- In testimony before the Food and Drug Administration (FDA), Gregory J. Dehmer, MD, president of the Society for Cardiovascular Angiography and Interventions (SCAI), today urged a review panel to evaluate new data on the safety of drug-eluting stents (DES) from the perspective of prior developments in the history of coronary intervention, and with an appreciation for the balance of benefits and risks that guides all clinical decision-making.

As president of SCAI, Dr. Dehmer spoke on behalf of the professional organization representing the vast majority of physicians who perform invasive cardiac procedures, including the placement of coronary artery stents. "SCAI has been and will continue to be at the forefront in providing guidance to physicians regarding the use of drug-eluting stents," said Dr. Dehmer, who cited the Societys proactive role in publishing clinical alert documents on drug-eluting stents and other therapies for patients with heart disease.

Drug-eluting stents were approved by the FDA in 2003. These devices, which prop open narrowed arteries in the heart, are coated with a medication that prevents the build-up of scar tissue inside the stent. Drug-eluting stents have proven so successful in preventing renarrowing of the artery or restenosis they were being used in 80 to 90 percent of stent procedures, thereby sparing patients the need for a repeat procedure to restore blood flow through a constricted artery.

A new concern has arisen, however. Several recent analyses that tracked patient outcomes for four to five years after stent placement showed that blood clots appear slightly more likely to form inside a drug-eluting stent than in a bare metal stent. When this occurs, the patient may suffer a heart attack or even die. "Clearly, this unexpected new observation is worrisome, but it must be evaluated in the proper context," said Dr. Dehmer, who has practiced as an intervention
'"/>

Contact: Wayne Powell
wpowell@scai.org
703-772-7910
Society for Cardiovascular Angiography and Interventions
7-Dec-2006


Page: 1 2 3

Related medicine news :

1. CHPA president and leading physician available to comment on NIDA Monitoring the Future
2. ARRS president responds to NAS report on ionizing radiation
3. Everyone is entitled to a good doctor, says former GMC president
4. MRI finds breast cancer before it becomes dangerous
5. Nonsmall cell lung cancer -- chemotherapy before surgery appears better than surgery alone
6. Researchers find deadly prescription drug effects 6 years before FDA
7. Intake of vitamin D and calcium associated with lower risk of breast cancer before menopause
8. Exposure to mercury preservatives before birth is no higher in children with autism
9. Chemotherapy more effective when given before breast cancer surgery
10. Physicians should be able to review performance rates before release
11. Brain structure changes years before memory loss begins

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: SCAI president testifies before FDA safety drug eluting stents

(Date:5/24/2013)... commonly used to treat glaucoma may cause droopy eyelids ... according to a new study. The drugs, known ... eye pressure, have already been shown to cause blurred ... said, suggesting that the new findings could lead to ... conservative when prescribing these drugs, the researchers added, particularly ...
(Date:5/24/2013)... of highly respected Alzheimer,s researchers failed to replicate what ... this brain disease when they were published last year ... presented online Feb. 9, 2012, suggested that the drug ... of beta amyloid plaques (Aβ) a pathological hallmark ... According to the authors of the 2012 report, drug ...
(Date:5/24/2013)... New York, New York (PRWEB) May 24, 2013 ... da Vinci lawsuit involving Intuitive Surgical Inc.’s da ... According to court records, a Washington State Court ... not committed negligence in training a surgeon who performed ... several years later. The patient’s family had alleged ...
(Date:5/24/2013)... 2013 Dwell Media LLC ... as Executive Vice President of Digital for Dwell Media. ... represented a large portion of Yahoo's global media business. ... develops a fully-integrated commerce unit to launch in 2014. ... digital content for leading firms in Silicon Valley. Dwell, ...
(Date:5/24/2013)... 24 (HealthDay News) -- People with high levels of ... die of liver disease than those with lower levels, ... cadmium in urine is evidence of long-term exposure to ... and tobacco smoke, the Johns Hopkins researchers explained. ... cadmium directly causes liver disease but instead suggest an ...
Breaking Medicine News(10 mins):Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 2Health News:Multiple research teams unable to confirm high-profile Alzheimer's study 3Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 2Health News:Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on Verdict in Nation’s First Trial Involving Alleged Da Vinci Complications 3Health News:Yahoo Commerce Head Joins Leadership at Dwell Media 2Health News:High Cadmium Levels May Raise Risk for Dying From Liver Disease: Study 2
(Date:5/24/2013)... -- The potential of the pulmonary route ... agents has been receiving undeniable attention with the recent ... The crucial formulation considerations for orally inhaled products together ... role in the efficiency of pulmonary delivery, and great ... formulation techniques and devices in recent years. ...
(Date:5/23/2013)... y PARÍS, 24 de mayo de 2013 /PRNewswire/ ... destacado desarrollador y fabricante de herramientas de precisión ... y tratamiento de la enfermedad vascular periférica y ... ADVISE ( Ad enosine V asodilator ... II durante la sesión de ensayo clínico hot ...
(Date:5/23/2013)... EDGE, N.J. , May 23, 2013 ... a commercial stage medical device company that develops and ... successful completion of its rights offering.  In addition, the ... March 2011 warrants expired on May 17, 2013. ... of $3.0 million from the rights offering.   A portion ...
Breaking Medicine Technology:Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
Cached News: